WALTHAM, Mass. and BOULDER, Colo., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.

Imvax, Inc. today announced an oral presentation and two poster presentations at the 2024 SNO Annual Meeting in Houston, Texas.

On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 –– Assembled Cardiovascular Scientific Advisory Board (CV ...

Planegg/Martinsried, November 11, 2024.Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused ...

The late-breaking poster presentation focused on results from a subset of ... the risk that the results of current preclinical studies and clinical trials may not be predictive of future results in ...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody ...

"My husband loves to go shop for my gifts." Woman seeks guidance for well-meaning husband's gift picks ahead of holiday ...

REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 ...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders ...

Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz ...